TR may be defined as cancers with a similar molecular receptor profile (ER; oestrogen receptor / PR; progesterone receptor / HER2) and histological subtype (Ductal/Lobular/ductal carcinoma in situ) when compared to the originally treated cancer. Here, PGR is linked to ductal breast carcinoma in situ.